These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32994204)

  • 1. Resolution of Spatial and Temporal Heterogeneity in Bevacizumab-Treated Breast Tumors by Eigenspectra Multispectral Optoacoustic Tomography.
    Liapis E; Klemm U; Karlas A; Reber J; Ntziachristos V
    Cancer Res; 2020 Dec; 80(23):5291-5304. PubMed ID: 32994204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic effects on breast tumor hemodynamics revealed by eigenspectra multispectral optoacoustic tomography (eMSOT).
    Liapis E; Karlas A; Klemm U; Ntziachristos V
    Theranostics; 2021; 11(16):7813-7828. PubMed ID: 34335966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry.
    Quiros-Gonzalez I; Tomaszewski MR; Aitken SJ; Ansel-Bollepalli L; McDuffus LA; Gill M; Hacker L; Brunker J; Bohndiek SE
    Br J Cancer; 2018 Apr; 118(8):1098-1106. PubMed ID: 29576623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.
    Quiros-Gonzalez I; Tomaszewski MR; Golinska MA; Brown E; Ansel-Bollepalli L; Hacker L; Couturier DL; Sainz RM; Bohndiek SE
    Cancer Res; 2022 Apr; 82(8):1658-1668. PubMed ID: 35404400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model.
    El-Hajjar L; Jalaleddine N; Shaito A; Zibara K; Kazan JM; El-Saghir J; El-Sabban M
    Cell Signal; 2019 Jan; 53():400-412. PubMed ID: 30445167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eigenspectra optoacoustic tomography achieves quantitative blood oxygenation imaging deep in tissues.
    Tzoumas S; Nunes A; Olefir I; Stangl S; Symvoulidis P; Glasl S; Bayer C; Multhoff G; Ntziachristos V
    Nat Commun; 2016 Jun; 7():12121. PubMed ID: 27358000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy.
    Rebelo de Almeida C; Mendes RV; Pezzarossa A; Gago J; Carvalho C; Alves A; Nunes V; Brito MJ; Cardoso MJ; Ribeiro J; Cardoso F; Ferreira MG; Fior R
    Commun Biol; 2020 Jun; 3(1):299. PubMed ID: 32523131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volumetric Optoacoustic Imaging Unveils High-Resolution Patterns of Acute and Cyclic Hypoxia in a Murine Model of Breast Cancer.
    Ron A; Deán-Ben XL; Gottschalk S; Razansky D
    Cancer Res; 2019 Sep; 79(18):4767-4775. PubMed ID: 31097477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
    Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS
    Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.
    Franco M; Man S; Chen L; Emmenegger U; Shaked Y; Cheung AM; Brown AS; Hicklin DJ; Foster FS; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3639-48. PubMed ID: 16585189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic drugs increase xenograft aggressiveness.
    Cancer Discov; 2012 Mar; 2(3):OF3. PubMed ID: 22586000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel strategies towards the use of anti-angiogenic agents in breast cancer.
    Bakker JL; Meijers-Heijboer H; Verheul H
    Eur J Pharmacol; 2013 Oct; 717(1-3):36-9. PubMed ID: 23545363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs.
    Hutchinson LG; Mueller HJ; Gaffney EA; Maini PK; Wagg J; Phipps A; Boetsch C; Byrne HM; Ribba B
    CPT Pharmacometrics Syst Pharmacol; 2016 Nov; 5(11):636-645. PubMed ID: 27863175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI.
    Zhu W; Kato Y; Artemov D
    PLoS One; 2014; 9(1):e86583. PubMed ID: 24466160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Resolution Multispectral Optoacoustic Tomography of the Vascularization and Constitutive Hypoxemia of Cancerous Tumors.
    Chekkoury A; Nunes A; Gateau J; Symvoulidis P; Feuchtinger A; Beziere N; Ovsepian SV; Walch A; Ntziachristos V
    Neoplasia; 2016 Aug; 18(8):459-67. PubMed ID: 27566102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep Learning-Based Spectral Unmixing for Optoacoustic Imaging of Tissue Oxygen Saturation.
    Olefir I; Tzoumas S; Restivo C; Mohajerani P; Xing L; Ntziachristos V
    IEEE Trans Med Imaging; 2020 Nov; 39(11):3643-3654. PubMed ID: 32746111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
    Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
    BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
    Kristian A; Revheim ME; Qu H; Mælandsmo GM; Engebråten O; Seierstad T; Malinen E
    Acta Oncol; 2013 Oct; 52(7):1566-72. PubMed ID: 23984812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients.
    Ueda S; Kuji I; Shigekawa T; Takeuchi H; Sano H; Hirokawa E; Shimada H; Suzuki H; Oda M; Osaki A; Saeki T
    PLoS One; 2014; 9(6):e98715. PubMed ID: 24905225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.